In this study, a series of dual CDK9/HDACi based on N-(2-aminophenyl)-5-(4-aryl-pyrimidin-2-yl)amino-1H-indole-2-carboxamide scaffolds was designed and synthesized to target transcriptional dysregulation in cancer. This evidence concerns the gene CDK9 and cancer.